Frank McCormick, Director at BridgeBio Pharma, Inc. (BBIO), sold 148,000 shares at $53.16 ($7.9M) on 2025-09-05, disclosed to the SEC on 2025-09-08.
Open-market sale of $7.9M BBIO by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $53.16 | 74,000 | $3.9M | 50.0% |
| 2 | $53.16 | 74,000 | $3.9M | 50.0% |
| Total | $53.16 avg | 148,000 | $7.9M | 100% |
| Filing → |
| BBIO | SELL | 2025-06-26 | $4.4M | — | Filing → |
| BBIO | SELL | 2023-12-28 | $4.2M | — | Filing → |
| BBIO | SELL | 2020-11-17 | $8.6M | — | Filing → |